All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2022-03-09.
From the record
Twist Bioscience Corporation's filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2022-03-09) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+55.9% a year over 9 filed years; profitable in 0 of 9.
From the record
Twist Bioscience Corporation's 9 filed years say what it did: revenue went from $11 million in fiscal 2017 to $377 million in fiscal 2025, up 55.9% a year; it rose in 8 of 8 years; it never fell from a peak; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.0/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Twist Bioscience Corporation's shareholder treatment is put at 8.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 20% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -16%: lost 16¢ per shareholder dollar. Leverage 26%: owes 26¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-09-30, Twist Bioscience Corporation lost about 16 cents for every dollar of shareholders' money, and gross profitability: its products earned about 30 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 26 cents per dollar of assets, and net share issuance: its share count grew 3.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 26% of 102 in its family; net margin -20.6%.
From the record
Twist Bioscience Corporation's standing among 102 graded names in its industry family: revenue of $377 million in fiscal 2025 ranks in the top 17% by size; a net margin of -20.6% ranks in the top 27%; revenue growth of 22.8% a year over the last 3 filed years ranks in the top 33% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 19% of 110 in its family for leadership; chief executive since 2018.
From the record
Twist Bioscience Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Leproust, Emily M. (Chief Executive Officer, as filed), filing under that title since 2018-10-30, 8 years (top 20% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 8 years (top 12%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 44% of 92 in its family for room to expand.
From the record
Twist Bioscience Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $185 million against no long-term debt tagged leaves 28.9% of its assets as net cash, top 48% of its family; cash from operations less capital spending is -20.1% of revenue (top 24%); a gross margin of 50.7% (bottom 29%); research spending of 21.3% of revenue (bottom 18%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 38% of 100 in its family for growth drivers.
From the record
Twist Bioscience Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 22.8% a year over the last three filed years against 55.9% over all 9, slowing (bottom 21% of its family); the newest year grew 20.3% (top 44%); research spending grew -12.6% a year (bottom 27%); capital spending grew -35% a year (bottom 46%) (its annual reports). Twist Bioscience Corporation reported 5 product lines in fiscal 2025: Ngs Tools at $208 million (55%), Synthetic Genes at $114 million (30%), Antibody Discovery at $23 million (6%), and 2 more; 4 of 5 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 43% of 72 in its family for expectations against reality.
From the record
Twist Bioscience Corporation's newest year against its own record: revenue of $377 million in fiscal 2025 came in 2.9% below the $388 million its prior three years' pace pointed to (bottom 43% of its family); net income of $78 million against a prior three-year average of $210 million (top 25%); a net margin of -20.6% against -85.7% before (top 47%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made